Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.
Nast
Alexander
A
Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité Universitätsmedizin Berlin, Campus Charité Mitte, Berlin. alexander.nast@charite.de
Augustin
Matthias
M
Boehncke
Wolf-Henning
WH
Klaus
Joachim
J
Mrowietz
Ulrich
U
Ockenfels
Hans-Michael
HM
Philipp
Sandra
S
Reich
Kristian
K
Rosenbach
Thomas
T
Schlaeger
Martin
M
Sebastian
Michael
M
Sterry
Wolfram
W
Streit
Volker
V
Weisenseel
Peter
P
Rzany
Berthold
B
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003880:Dermatology / Q000592:standards*; D005062:European Union; D019317:Evidence-Based Medicine; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab